FDA Brief

Warning letters Drugs

FDA warning letter to

Professional Disposables International, Inc.

High riskIssued Jan 7, 2022Posted Jan 18, 2022Division of Pharmaceutical Quality Operations I

Professional Disposables International, a New York drug manufacturer, failed to properly investigate out-of-specification test results for Prevantics antiseptic swabs and Povidone-Iodine products.

What happened

FDA inspected the Orangeburg, NY facility over many days between May 5 and June 23, 2021. Investigators found the company did not adequately investigate failing (out-of-specification) test results, invalidating about 55 of 78 such results between May 2019 and May 2021 without solid scientific evidence. FDA also found the company did not file required Field Alert Reports with the agency for distributed batches that failed strength tests, and did not extend a Povidone-Iodine recall to Prevantics Swabstick, Maxi Swabstick and Swab, which also failed assay specifications.

What FDA found

  1. The company failed to thoroughly investigate batches that did not meet specifications, invalidating roughly 55 of 78 out-of-specification results over two years without adequate scientific justification.

    21 CFR 211.192
  2. Batch 12000124 of Prevantics Swabstick was released on a passing retest after the failing result was blamed on a pipetting or dilution error, even though no glassware was kept as evidence.

    21 CFR 211.192
  3. Investigations were not extended to other potentially affected batches, and no corrective and preventive actions were started at the end of the investigations.

    21 CFR 211.192
  4. The company did not submit Field Alert Reports to FDA within three working days for distributed batches 12000124, 11900228ES and 11800257JS that failed assay specifications.

    21 CFR 314.81(b)(1)(i) and (ii); section 505(k) of the FD&C Act [21 U.S.C. 355(k)]
  5. The annual report for NDA 21524 reported an incorrect passing assay result, and neither a Field Alert Report nor an amendment to the annual report was submitted.

    21 CFR 314.81
  6. The revised procedure for handling out-of-specification results (version 9) is still deficient because it does not make clear how or when a production investigation must be started.

    21 CFR 211.192

What FDA wants

FDA asks the company to reply in writing within 15 working days with an independent assessment of its investigation system and an action plan, a revised procedure for when failing lab results trigger a production investigation, a retrospective review of all invalidated out-of-specification results for U.S. products over the past three years, retain-sample test results, and a Field Alert Report procedure with staff training. The company must also say whether it plans to resume Povidone-Iodine manufacturing for the U.S. market.

Who should pay attention

  • brands and distributors that buy finished OTC antiseptic products from contract manufacturers
  • companies relying on a contract manufacturer's handling of failing test results
  • NDA holders responsible for filing Field Alert Reports with FDA

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  2. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  3. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  4. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk